Operationalizing Subcutaneous Checkpoint Inhibitors in Practice. Implementing subcutaneous checkpoint inhibitors requires ...
Data from a large prospective study identified male and older patients as being more likely to develop CIP and 34% of cases ...
Chemotherapy-induced myelosuppression (CIM) significantly impacts quality of life for patients with cancer and leads to ...
A preliminary analysis of patient-reported outcomes for emotional functioning (EF) in patients with solid tumors revealed ...
Long-term NATALEE data show adjuvant ribociclib plus an aromatase inhibitor improves invasive disease–free survival vs AI ...
On this episode of Onc Nurse On Call, Kristin Daly, MSN, ANP-BC, AOCNP, discusses practical cancer care strategies in the age ...
She emphasized that while elacestrant has properties similar to other agents, imlunestrant is closer to a “pure” ER ...
Buparlisib combined with paclitaxel failed to improve overall survival vs paclitaxel alone for patients with PD-1/PD-L1–pretreated HNSCC. The combination of buparlisib and paclitaxel did not show an ...
Adding perioperative durvalumab to neoadjuvant chemotherapy did not worsen health-related quality of life for patients with muscle-invasive bladder cancer. Michiel van der Heijden, MD, PhD, medical ...
Patient-reported outcomes showed that health-related QOL stayed at baseline for patients with HRRM-positive mHSPC receiving a niraparib regimen. Health-related quality of life (HR-QOL) remained at ...
Atezolizumab Subcutaneous Data and Implementation Considerations. The subcutaneous formulation of atezolizumab (PD-L1 inhibitor) received approval approximately 1 year ago based o ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback